Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01763190 · ClinicalTrials.gov registry record · Phase 1
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01763190 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 36 participants.
The verdict
NCT01763190, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
Primary Objective: To study the effect of mild, moderate and severe renal impairment on the pharmacokinetics of SAR302503. Secondary Objective: To assess the tolerability of SAR302503 given as a single 300 mg dose in subjects with mild, moderate and severe renal impairment and in matched subjects with normal renal function.
Interventions
- DRUG SAR302503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01763190
The ClinicalTrials.gov registry entry for NCT01763190 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAR302503 is the first listed.
NCT01763190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01763190 about?
NCT01763190 is a clinical study titled "Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment". Primary Objective: To study the effect of mild, moderate and severe renal impairment on the pharmacokinetics of SAR302503. Secondary Objective: To assess the tolerability of SAR302503 given as a single 300 mg dose in subjects with mild, moderate and severe renal impairment and in matched subjects...
What is the current status of trial NCT01763190?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2012-11. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01763190?
The interventions under investigation include: SAR302503 (DRUG).
Who is sponsoring clinical trial NCT01763190?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.